Business
Bellus Health announces scheduled settlement of convertible notes
Bellus Health announces scheduled settlement of convertible notes Bellus Health an...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nBellus Health announces scheduled settlement of convertible notes\n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\n\n\n\n\n\nBellus Health announces scheduled settlement of convertible notes\nCanada NewsWire\nLAVAL, QC, Jan. 1, 2016\n\n\n\n\n- Issuance of 7,286,828 common shares in settlement of convertible notes\n -\n\n\nLAVAL, QC, Jan. 1, 2016 /CNW/ - BELLUS Health Inc. (TSX: BLU) (BELLUS\n Health or the Company), a drug development company focused on rare\n diseases, today announced the scheduled issuance of 7,286,828 common\n shares from treasury to Victoria Square Ventures Inc. (VSVI) in\n settlement of convertible notes. The settlement further simplifies the\n Company's capital structure.\n\n\nThe convertible notes' notional amount was approximately $10.9 million\n and terms of the conversion were determined as part of BELLUS Health's\n capital reorganization in 2012. Subsequent to the settlement, VSVI now\n holds 32.5% of the Company's issued and outstanding common shares and\n 27.0% on a fully diluted basis.\n\n\n\"The settlement of these convertible notes is the penultimate step to\n the completion of our capital structure's simplification that started\n in 2012\", said Roberto Bellini, President and Chief Executive Officer\n of BELLUS Health. \"We expect that the conversion of the second and\n final equity-like instrument, being the Pharmascience Exchange Right,\n will occur by the fourth quarter of 2016.\"\n\n\nThe Company now has approximately 54.7 million common shares outstanding\n and 65....